NCT03332459View on ClinicalTrials.gov

A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 5, 2018

Primary Completion Date

April 13, 2020

Study Completion Date

April 13, 2020

Conditions
Respiratory Syncytial Virus Infections
Interventions
DRUG

Lumicitabine

Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.

DRUG

Placebo

Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.

Trial Locations (4)

721-8511

Fukuyama City Hospital, Fukuyama

036-8545

Hirosaki National Hospital, Hirosaki

945-8585

National Hospital Organization Niigata National Hospital, Niigata

874-0011

National Hospital Organization Beppu Medical Center, Ōita

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03332459 - A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection | Biotech Hunter | Biotech Hunter